hamartin Activators
The emerging class of hamartin activators encompasses a diverse array of compounds designed to selectively stimulate the activation of hamartin, a critical component of the tuberous sclerosis complex (TSC) signaling pathway. Among these activators are compounds like Rapamycin, Temsirolimus, GDC-0349, Torin 2, Palomid 529, Sapanisertib, INK-128, KU-0063794, MHY1485, and WYE-687, each influencing hamartin through specific interactions within the mTOR pathway. Rapamycin, for example, indirectly activates hamartin by inhibiting the mTOR pathway. Its inhibition of mTOR prevents downstream phosphorylation events, releasing negative feedback on hamartin and facilitating its activation. Similarly, Temsirolimus, a selective mTORC1 inhibitor, disrupts mTORC1 signaling, leading to the activation of hamartin. GDC-0349, Torin 2, Palomid 529, Sapanisertib, INK-128, KU-0063794, MHY1485, and WYE-687 follow suit by modulating mTORC1 and mTORC2, providing a comprehensive approach to hamartin activation.
These activators offer valuable insights into the intricate regulation of the mTOR pathway and its impact on hamartin activity. The specific influences of these compounds on hamartin activation through well-defined signaling pathways provide a foundation for further exploration into the dynamic nature of cellular signaling networks and their implications for various physiological and pathological contexts. The diverse array of hamartin activators presents a nuanced understanding of their potential roles in modulating cellular responses, highlighting their significance in the intricate tapestry of signal transduction pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ridaforolimus | 572924-54-0 | sc-212783 | 5 mg | $248.00 | 1 | |
Ridaforolimus, an mTOR inhibitor, indirectly activates hamartin by disrupting the mTOR pathway. Inhibition of mTOR prevents the phosphorylation of downstream effectors, relieving negative feedback on hamartin and leading to its activation. This compound offers a targeted approach to modulating hamartin activity in the context of mTOR signaling regulation. | ||||||
N-Ethyl-N′-[4-[5,6,7,8-tetrahydro-4-[(3S)-3-methyl-4-morpholinyl]-7-(3-oxetanyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]urea | 1207360-89-1 | sc-496573 | 5 mg | $480.00 | ||
Also called GDC-0349, this compound is an mTORC1 inhibitor, indirectly activates hamartin by disrupting the mTORC1 complex. Inhibition of mTORC1 prevents downstream phosphorylation events, releasing negative feedback on hamartin and promoting its activation. GDC-0349 presents a specific approach to modulating hamartin activity within the mTORC1 signaling pathway. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
Palomid 529, an mTORC1 and mTORC2 inhibitor, indirectly activates hamartin by disrupting both mTOR complexes. Inhibition of mTORC1 and mTORC2 prevents downstream phosphorylation events, releasing negative feedback on hamartin and promoting its activation. Palomid 529 offers a comprehensive means to modulate hamartin within the mTOR signaling pathway. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
KU-0063794, an ATP-competitive mTOR inhibitor, indirectly activates hamartin by disrupting the mTORC1 complex. Inhibition of mTORC1 prevents downstream phosphorylation events, relieving negative feedback on hamartin and leading to its activation. KU-0063794 provides a specific means to modulate hamartin within the mTORC1 signaling pathway. | ||||||
MHY1485 | 326914-06-1 | sc-507522 | 10 mg | $140.00 | ||
MHY1485, an mTOR activator, directly influences hamartin by promoting mTORC1 activation. This compound stimulates mTORC1 signaling, leading to downstream phosphorylation events and positive feedback on hamartin, ultimately resulting in its activation. MHY1485 offers a unique activatory approach to modulating hamartin within the mTOR pathway. | ||||||
WYE-687 | 1062161-90-3 | sc-364653 sc-364653A | 10 mg 50 mg | $235.00 $992.00 | ||
WYE-687, an mTOR inhibitor, indirectly activates hamartin by disrupting the mTORC1 complex. Inhibition of mTORC1 prevents downstream phosphorylation events, relieving negative feedback on hamartin and leading to its activation. WYE-687 provides a focused approach to modulating hamartin within the context of mTORC1 signaling. | ||||||